Latest Revenue Growth News

Vitasora Health Limited reported a significant 22% increase in daily clinical billing productivity for the December 2025 quarter, alongside a 17% rise in operating revenue. With new CMS reimbursement policies now in effect, the company anticipates a further 10–20% revenue uplift in 2026.

Doctor Care Anywhere reported steady consultation growth and a third consecutive quarter of positive cashflow in Q4 2025, while advancing digital health pilots and reaffirming ambitious medium-term revenue and profitability goals.

ImpediMed reported a solid Q2 FY26 with $3.9 million in revenue and significant reimbursement gains for its lymphoedema technology, while launching new US Heart Health and Wellness initiatives.

ikeGPS Group has reported a robust 35% increase in its platform subscription revenue exit run rate for the nine months to December 2025, reaffirming its FY26 growth guidance amid strong market demand and new AI-driven product launches.

Complii FinTech Solutions reported a solid 6.6% annual increase in recurring revenue and unveiled the first stage of a major CRM overhaul, signaling a strategic push to enhance its capital raising and compliance platform.

Spenda Limited reports a 65% year-on-year jump in payment volumes and a 34% quarterly rise in cash receipts, alongside significant cost savings and leadership changes.

Aeeris Ltd has reported a profitable second quarter for FY26, with total unadjusted revenue rising 61% year-on-year to $1.54 million and annual recurring revenue climbing 16.5% to nearly $4 million. The company’s operational advances and disciplined cost control underpin a promising path to sustainable profitability.

Tinybeans Group’s acquisition of US-based Qeepsake fuels a sharp revenue jump and improved profitability in Q2 FY26, signalling early success in its growth strategy.

Atomo Diagnostics reported a robust 121% quarter-on-quarter revenue increase to $1.5 million, driven by new orders for its FebriDx Pascal and HIV Self-Test products. The company also secured a global licensing deal for a novel liver function test and expanded manufacturing capacity to support growing demand.

Stakk Limited has surged to an $8.53 million annual recurring revenue run-rate in 2025, propelled by its acquisition of Radical DBX and strong SaaS growth. The fintech’s strategic moves position it for breakeven and further expansion in 2026.

ASX Limited has updated its FY26 expense growth guidance upwards, reflecting increased investments in risk management and technology modernisation alongside ASIC Inquiry-related costs, while reporting strong unaudited 1H26 revenue growth.

Emyria Limited has reported strong quarterly revenue growth driven by the expansion of its Empax clinic network across multiple Australian states, supported by a recent $8 million institutional placement to fund its national rollout and workforce expansion.